Financhill
Back

Reata Pharmaceuticals 10K Form

Sell
29

RETA
Reata Pharmaceuticals

Last Price:
24.53
Seasonality Move:
29.1%

7 Day Trial

ALL ACCESS PASS

$ 7

Receive RETA News And Ratings

See the #1 stock for the next 7 days that we like better than RETA

RETA Financial Statistics

Sales & Book Value

Annual Sales: $11.49M
Cash Flow: $-51.4M
Price / Cash Flow: 0
Annual Sales: $1.88
Price / Book: 13.01

Profitability

EPS (TTM): -8.37000
Net Income (TTM): $-304.63M
Gross Margin: $11.49M
Return on Equity: -159.96%
Return on Assets: -42.83%

Reata Pharmaceuticals Earnings Forecast

Key Reata Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 6 years for RETA is 100.00%.
  • The Selling, General & Administrative Expenses for RETA have been equal to 861.62% of Gross Profit Margin.
  • The Research & Development expenses have been 1,357.62% of Revenue.
  • The Interest Expense is -17.91% of Operating Income.
  • The Net Earning history of RETA is -2,588.25% of Total Revenues.
  • Per Share Earnings over the last 9 years have been positive in 2 years.

Reata Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
Current Symbol: RETA
CUSIP: 75615P
Website: reatapharma.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 10.6
Quick Ratio: 10.39

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RETA Technical Analysis vs Fundamental Analysis

Sell
29
Reata Pharmaceuticals (RETA) is a Sell

Is Reata Pharmaceuticals a Buy or a Sell?